Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”

Learn more »

Cellceutix’s Clinical Trials

Learn more »

Prurisol for Psoriasis Planned- Phase 2/3 under FDA 505(b)(2)

Learn more »

Leading Antibiotic Technologies Licensed From University of Pennsylvania

Learn more »

Cellceutix Takes on Klebsiella Pneumoniae, One of the World’s Most Dangerous Superbugs

Learn more »

From the CEO’s Desk


My fellow Cellceutix shareholders,

As I do periodically, I’d like to take a moment to discuss some of our accomplishments over the past year and update everyone on the current position of our company ...

Read More »

Our Technology

Our technology - Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression.

Read more »

Our technology KM-133 acts through immune modulation and PRINS reduction

Read more »

Our technology - Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics

Read more »

Email Alerts

Sign Up to Receive Alerts on Cellceutix click here.

Clinical Trials

More information available at clinicaltrials.gov

Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin